Clinical Trial Update: A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating treatment for Idiopathic Thrombocytopenic Purpura patients who do not have a durable response to Rituxan has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Idiopathic Thrombocytopenic Purpura (ITP) | Phase 2 | Status: WITHDRAWN